1. Market Research
  2. > Percutaneous Coronary Intervention - Pipeline Review, H2 2013

Percutaneous Coronary Intervention - Pipeline Review, H2 2013

  • October 2013
  • -
  • Global Markets Direct
  • -
  • 48 pages

Percutaneous Coronary Intervention - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Percutaneous Coronary Intervention - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Percutaneous Coronary Intervention, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Percutaneous Coronary Intervention. Percutaneous Coronary Intervention - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Percutaneous Coronary Intervention.
- A review of the Percutaneous Coronary Intervention products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Percutaneous Coronary Intervention pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Percutaneous Coronary Intervention.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Percutaneous Coronary Intervention pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Percutaneous Coronary Intervention - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Percutaneous Coronary Intervention Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Percutaneous Coronary Intervention 7
Percutaneous Coronary Intervention Therapeutics under Development by Companies 9
Late Stage Products 10
Comparative Analysis 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Percutaneous Coronary Intervention Therapeutics - Products under Development by Companies 12
Companies Involved in Percutaneous Coronary Intervention Therapeutics Development 13
F. Hoffmann-La Roche Ltd. 13
AstraZeneca PLC 14
Momenta Pharmaceuticals, Inc. 15
Viron Therapeutics, Inc. 16
Lee's Pharmaceutical Holdings Limited 17
Percutaneous Coronary Intervention - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Drug Profiles 23
adomiparin - Drug Profile 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
VT-111a - Drug Profile 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
cangrelor - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
inclacumab - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
ZK-001 - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
Percutaneous Coronary Intervention Therapeutics - Drug Profile Updates 33
Percutaneous Coronary Intervention Therapeutics - Discontinued Products 36
Percutaneous Coronary Intervention Therapeutics - Dormant Products 37
Percutaneous Coronary Intervention - Product Development Milestones 38
Featured News and Press Releases 38
Oct 09, 2013: The Medicines Company Completes Two Pharmacodynamic Trials Testing Transition of Intravenous Antiplatelet Cangrelor to Oral Ticagrelor and Prasugrel 38
Sep 17, 2013: Regado Biosciences Enrolls First Patient in Phase 3 Trial of REG1 38
Sep 03, 2013: Totality of Data From Three Phase III Trials of The Medicines Company's Intravenous Cangrelor Presented and Published 39
Jun 18, 2013: Daiichi Sankyo Submits New Drug Application In Japan For Antiplatelet Agent Prasugrel 40
Mar 16, 2013: Daiichi Sankyo Announces Positive Phase III Study Results For Prasugrel In Japanese Patients With Acute Coronary Syndrome Undergoing PCI 41
Mar 14, 2013: Daiichi Sankyo Announces Results From Phase III Study Of Prasugrel And Aspirin In Elective Patients With Stable Angina And Chronic Myocardial Infarction Undergoing PCI 42
Mar 10, 2013: The Medicines Company's Intravenous Cangrelor Demonstrates 22% Reduction In Ischemic Events In Patients Undergoing Percutaneous Coronary Intervention 43
Jan 08, 2013: The Medicines Company Announces Positive Results From Phase III Trial Of Cangrelor For Treatment Of Patients Undergoing Percutaneous Coronary Intervention 44
Oct 23, 2012: Daiichi Sankyo And Eli Lilly Announce Results From New Retrospective Studies In Acute Coronary Syndromes-Percutaneous Coronary Intervention Patients Treated With Effient 44
Jul 02, 2012: The Medicines Company Expects Cangrelor Phase III Trial Enrollment Completion In 2012 46
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 48
Disclaimer 48



List of Tables

Number of Products Under Development for Percutaneous Coronary Intervention, H2 2013 7
Products under Development for Percutaneous Coronary Intervention - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Comparative Analysis by Late Stage Development, H2 2013 10
Comparative Analysis by Mid Clinical Stage Development, H2 2013 11
Products under Development by Companies, H2 2013 12
F. Hoffmann-La Roche Ltd., H2 2013 13
AstraZeneca PLC, H2 2013 14
Momenta Pharmaceuticals, Inc., H2 2013 15
Viron Therapeutics, Inc., H2 2013 16
Lee's Pharmaceutical Holdings Limited, H2 2013 17
Assessment by Monotherapy Products, H2 2013 18
Assessment by Stage and Route of Administration, H2 2013 20
Assessment by Stage and Molecule Type, H2 2013 22
Percutaneous Coronary Intervention Therapeutics - Drug Profile Updates 33
Percutaneous Coronary Intervention Therapeutics - Discontinued Products 36
Percutaneous Coronary Intervention Therapeutics - Dormant Products 37



List of Figures

Number of Products under Development for Percutaneous Coronary Intervention, H2 2013 7
Products under Development for Percutaneous Coronary Intervention - Comparative Analysis, H2 2013 8
Products under Development by Companies, H2 2013 9
Late Stage Products, H2 2013 10
Mid Clinical Stage Products, H2 2013 11
Assessment by Monotherapy Products, H2 2013 18
Assessment by Route of Administration, H2 2013 19
Assessment by Stage and Route of Administration, H2 2013 20
Assessment by Molecule Type, H2 2013 21
Assessment by Stage and Molecule Type, H2 2013 22



Companies Mentioned

F. Hoffmann-La Roche Ltd.
AstraZeneca PLC
Momenta Pharmaceuticals, Inc.
Viron Therapeutics, Inc.
Lee's Pharmaceutical Holdings Limited

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.